vs
Side-by-side financial comparison of FEDERAL AGRICULTURAL MORTGAGE CORP (AGM) and Vericel Corp (VCEL). Click either name above to swap in a different company.
FEDERAL AGRICULTURAL MORTGAGE CORP is the larger business by last-quarter revenue ($107.5M vs $92.9M, roughly 1.2× Vericel Corp). On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 6.1%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 7.1%).
The Federal Agricultural Mortgage Corporation, also known as Farmer Mac, is a stockholder-owned, federally chartered corporation established by the U.S. Congress in 1988 under the Agricultural Credit Act of 1987. It was created to establish a secondary market for agricultural real estate and housing mortgage loans, to increase liquidity and the availability of long-term, stable credit for farmers, ranchers, and rural communities.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
AGM vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $107.5M | $92.9M |
| Net Profit | — | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 56.3% | 24.1% |
| Net Margin | — | 25.0% |
| Revenue YoY | 6.1% | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $3.69 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $107.5M | $92.9M | ||
| Q3 25 | $104.0M | $67.5M | ||
| Q2 25 | $102.6M | $63.2M | ||
| Q1 25 | $94.3M | $52.6M | ||
| Q4 24 | $101.3M | $75.4M | ||
| Q3 24 | $90.3M | $57.9M | ||
| Q2 24 | $89.9M | $52.7M | ||
| Q1 24 | $93.7M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $55.0M | $5.1M | ||
| Q2 25 | $54.8M | $-553.0K | ||
| Q1 25 | $49.7M | $-11.2M | ||
| Q4 24 | $56.5M | $19.8M | ||
| Q3 24 | $49.8M | $-901.0K | ||
| Q2 24 | $47.1M | $-4.7M | ||
| Q1 24 | $53.7M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 56.3% | 24.1% | ||
| Q3 25 | 64.1% | 5.1% | ||
| Q2 25 | 63.8% | -3.2% | ||
| Q1 25 | 66.9% | -24.3% | ||
| Q4 24 | 67.5% | 24.5% | ||
| Q3 24 | 69.0% | -4.3% | ||
| Q2 24 | 65.9% | -11.5% | ||
| Q1 24 | 72.8% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | 52.9% | 7.5% | ||
| Q2 25 | 53.4% | -0.9% | ||
| Q1 25 | 52.6% | -21.4% | ||
| Q4 24 | 55.8% | 26.3% | ||
| Q3 24 | 55.2% | -1.6% | ||
| Q2 24 | 52.4% | -8.9% | ||
| Q1 24 | 57.4% | -7.5% |
| Q4 25 | $3.69 | $0.46 | ||
| Q3 25 | $4.44 | $0.10 | ||
| Q2 25 | $4.48 | $-0.01 | ||
| Q1 25 | $4.01 | $-0.23 | ||
| Q4 24 | $4.62 | $0.40 | ||
| Q3 24 | $3.86 | $-0.02 | ||
| Q2 24 | $3.68 | $-0.10 | ||
| Q1 24 | $4.28 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | $30.8B | — |
| Stockholders' EquityBook value | $1.7B | $354.6M |
| Total Assets | $35.4B | $488.0M |
| Debt / EquityLower = less leverage | 17.93× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | $842.1M | $101.7M | ||
| Q2 24 | $923.0M | $102.5M | ||
| Q1 24 | $745.1M | $110.6M |
| Q4 25 | $30.8B | — | ||
| Q3 25 | $29.2B | — | ||
| Q2 25 | $28.9B | — | ||
| Q1 25 | $28.0B | — | ||
| Q4 24 | $27.5B | — | ||
| Q3 24 | $27.2B | — | ||
| Q2 24 | $26.8B | — | ||
| Q1 24 | $26.8B | — |
| Q4 25 | $1.7B | $354.6M | ||
| Q3 25 | $1.7B | $321.9M | ||
| Q2 25 | $1.5B | $306.8M | ||
| Q1 25 | $1.5B | $295.5M | ||
| Q4 24 | $1.5B | $292.0M | ||
| Q3 24 | $1.5B | $257.5M | ||
| Q2 24 | $1.5B | $243.0M | ||
| Q1 24 | $1.5B | $233.9M |
| Q4 25 | $35.4B | $488.0M | ||
| Q3 25 | $33.4B | $453.3M | ||
| Q2 25 | $33.0B | $435.6M | ||
| Q1 25 | $31.8B | $424.6M | ||
| Q4 24 | $31.3B | $432.7M | ||
| Q3 24 | $30.6B | $390.4M | ||
| Q2 24 | $30.2B | $376.8M | ||
| Q1 24 | $29.8B | $356.7M |
| Q4 25 | 17.93× | — | ||
| Q3 25 | 17.31× | — | ||
| Q2 25 | 18.70× | — | ||
| Q1 25 | 18.39× | — | ||
| Q4 24 | 18.48× | — | ||
| Q3 24 | 18.60× | — | ||
| Q2 24 | 17.87× | — | ||
| Q1 24 | 18.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.1M | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | 0.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.1M | $15.0M | ||
| Q3 25 | $74.2M | $22.1M | ||
| Q2 25 | $-47.7M | $8.2M | ||
| Q1 25 | $-49.8M | $6.6M | ||
| Q4 24 | $612.6M | $22.2M | ||
| Q3 24 | $-44.4M | $10.2M | ||
| Q2 24 | $56.1M | $18.5M | ||
| Q1 24 | $233.3M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | $607.4M | $8.5M | ||
| Q3 24 | $-44.4M | $-9.2M | ||
| Q2 24 | $52.6M | $1.8M | ||
| Q1 24 | $231.7M | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | 599.8% | 11.2% | ||
| Q3 24 | -49.2% | -15.9% | ||
| Q2 24 | 58.5% | 3.4% | ||
| Q1 24 | 247.3% | -13.3% |
| Q4 25 | 0.0% | 2.4% | ||
| Q3 25 | 0.0% | 3.9% | ||
| Q2 25 | 0.0% | 12.9% | ||
| Q1 25 | 0.0% | 27.0% | ||
| Q4 24 | 5.2% | 18.3% | ||
| Q3 24 | 0.1% | 33.5% | ||
| Q2 24 | 4.0% | 31.8% | ||
| Q1 24 | 1.7% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | 1.35× | 4.35× | ||
| Q2 25 | -0.87× | — | ||
| Q1 25 | -1.00× | — | ||
| Q4 24 | 10.84× | 1.12× | ||
| Q3 24 | -0.89× | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | 4.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGM
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
